Breaking News, Collaborations & Alliances

Catamaran Bio, OmniaBio Partner to Advance Allogeneic CAR-NK Cell Therapies

To develop and manufacture Catamaran Bio’s allogeneic chimeric antigen receptor (CAR)-NK cell therapies for the treatment of solid tumors.

Catamaran Bio Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, entered into a partnership with OmniaBio Inc., a contract development and manufacturing organization (CDMO) focused on cell and gene therapy, to develop and manufacture Catamaran Bio’s allogeneic chimeric antigen receptor (CAR)-NK cell therapies for the treatment of solid tumors. “This collaboration will allow us to develop scalable processes for the robust GMP manufacture of our off-the-sh...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters